Inrebic (fedratinib) Patient Assistance Program
Don’t let the high cost of brand JAK2 inhibitor disrupt your myelofibrosis treatment. We help eligible patients access Inrebic (fedratinib capsules) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Inrebic (fedratinib) is FDA-approved for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. Oral JAK2-selective inhibitor — alternative to ruxolitinib for first-line or after ruxolitinib failure/intolerance.
- Without assistance, Inrebic costs commonly run approximately $13,000–$17,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Inrebic for a flat $69.95 per month.
- Other JAK inhibitors for myelofibrosis: ruxolitinib (Jakafi — JAK1/2 inhibitor, established first-line; also for polycythemia vera and steroid-refractory acute and chronic GVHD), pacritinib (Vonjo — for thrombocytopenic myelofibrosis with platelets <50,000), momelotinib (Ojjaara — for anemic myelofibrosis, also addresses anemia via ACVR1/ALK2 inhibition). Allogeneic stem cell transplantation (allo-SCT) remains the only potentially curative therapy — consider for eligible patients. Supportive care: transfusions, ESAs, danazol (generic), iron chelators (deferasirox/Jadenu, deferoxamine, deferiprone) for transfusion-dependent anemia. Hydroxyurea (generic, cheap) historically used for cytoreduction but does not improve symptoms.
What is Inrebic Prescription Assistance Program?
The Inrebic Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Inrebic (used for intermediate-2 or high-risk primary or secondary myelofibrosis) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, hematology coordination, supporting documentation including risk stratification (DIPSS/MIPSS scoring) and JAK2/CALR/MPL status, and ongoing renewal — which can be overwhelming when you are managing chronic myelofibrosis.
At AffordMyPrescriptions, our Patient Advocates handle the entire Inrebic PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your hematologist for required medical documentation, follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Inrebic JAK2 inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Inrebic enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your myelofibrosis treatment.
Pharmacy Price Comparison
- Without assistance, Inrebic costs thousands of dollars per month at specialty pharmacies. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted myelofibrosis therapy accessible if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Inrebic advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic hydroxyurea (supportive) | ~$15/mo | Generic cytoreduction supportive |
| Walgreens | ~$16,500/mo | Save substantially |
| CVS Pharmacy | ~$17,000/mo | Save substantially |
| Walmart | ~$14,000/mo | Save substantially |
| Specialty pharmacy | ~$13,000/mo | Save substantially |
| Jakafi (alt — established) | ~$16,500/mo | Alt JAK1/2 established first-line |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Inrebic — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Inrebic Prescription Program?
The Inrebic Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Allogeneic SCT remains the only potentially curative therapy — consider transplant evaluation in eligible patients.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Inrebic assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Inrebic is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Inrebic:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $13,000–$17,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Inrebic assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Inrebic Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Inrebic:
Inrebic is a selective JAK2 inhibitor with activity against FLT3 — designed to address splenomegaly and constitutional symptoms in myelofibrosis. Approved for intermediate-2 and high-risk primary or secondary myelofibrosis. Provides an alternative to ruxolitinib for first-line or for patients who fail or are intolerant to ruxolitinib. JAKARTA and JAKARTA-2 trials established efficacy in JAK inhibitor-naive and ruxolitinib-resistant/intolerant patients.
How It Works:
Myelofibrosis is a chronic myeloproliferative neoplasm driven by JAK2 V617F (~60% of patients), CALR (~25%), or MPL (~10%) mutations — all leading to constitutive JAK/STAT signaling. Manifestations include splenomegaly, constitutional symptoms (fatigue, night sweats, weight loss, fevers), progressive bone marrow fibrosis, cytopenias (especially anemia and thrombocytopenia), and risk of leukemic transformation. Fedratinib selectively inhibits JAK2 and FLT3 — blocks constitutive JAK/STAT signaling driving myeloproliferation. Reduces splenomegaly, improves constitutional symptoms, and provides clinical benefit in JAK inhibitor-naive patients (JAKARTA) and after ruxolitinib failure/intolerance (JAKARTA-2). Does not modify the underlying clonal disease or prevent disease progression — allogeneic SCT remains the only potentially curative option.
Form and Use:
Inrebic 100 mg capsules. Recommended dose 400 mg (4 capsules) once daily. Take with or without food (high-fat meal may reduce nausea). Continue until disease progression or unacceptable toxicity. Mandatory baseline thiamine (vitamin B1) level — supplement if deficient before starting, due to boxed warning for encephalopathy including Wernicke’s encephalopathy. Monitor thiamine periodically and supplement. Periodic CBC, comprehensive metabolic panel including amylase/lipase, liver enzymes. Dose modifications for cytopenias, hepatic, pancreatic, and other toxicities.
Generic Availability:
No generic Inrebic. Other JAK inhibitors for myelofibrosis: ruxolitinib (Jakafi — JAK1/2, established first-line per COMFORT-I and COMFORT-II; also FDA-approved for polycythemia vera and acute/chronic GVHD), pacritinib (Vonjo — for thrombocytopenic MF with platelets <50,000 per PERSIST-2), momelotinib (Ojjaara — for anemic MF, dual JAK and ACVR1/ALK2 inhibition addressing anemia per MOMENTUM and SIMPLIFY trials). Allogeneic stem cell transplantation (allo-SCT) — only potentially curative — consider for eligible patients. Supportive care: red cell transfusions, ESAs (erythropoiesis-stimulating agents), danazol (generic — anabolic steroid for anemia), iron chelators (deferasirox/Jadenu, deferoxamine, deferiprone) for transfusion-dependent iron overload, hydroxyurea generic (cytoreduction, particularly for symptomatic disease in older patients not transplant candidates), splenectomy or splenic irradiation for refractory splenomegaly. Newer agents in development: BET inhibitors (pelabresib), navitoclax, imetelstat.
Warnings:
Boxed warning: serious and fatal encephalopathy, including Wernicke’s encephalopathy — caused by thiamine deficiency exacerbated by Inrebic; mandatory baseline thiamine assessment and supplementation if deficient before starting; ongoing monitoring and supplementation; immediate discontinuation if encephalopathy suspected (mental status changes, ataxia, ocular abnormalities). Other: anemia (very common, dose-limiting — may require transfusions), thrombocytopenia and bleeding (monitor; hold for severe; concurrent anticoagulant/antiplatelet caution), gastrointestinal toxicity (diarrhea, nausea, vomiting, constipation — manage proactively), hepatic toxicity (monitor LFTs; hold for severe), amylase/lipase elevation and pancreatitis (monitor), increased infection risk (PML/JC virus reactivation reported — rare), embryo-fetal toxicity. Drug interactions: strong dual CYP3A4 inhibitors (e.g., ketoconazole) increase fedratinib — reduce dose; strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) reduce efficacy — avoid.
FAQ (Frequently Asked Questions)
How much does Inrebic cost without insurance?
$13,000–$17,000 per month. Annual cost can exceed $200,000 without assistance. Specialty pharmacy and Patient Assistance Programs are essential.
Is Inrebic considered chemotherapy?
No — Inrebic is a targeted oral therapy (JAK2 inhibitor) — not traditional cytotoxic chemotherapy. Reduces splenomegaly and symptoms but does not eliminate the underlying clonal disease — allogeneic stem cell transplant remains the only potentially curative therapy.
What is the difference between Inrebic and Jakafi (ruxolitinib)?
Both JAK inhibitors. Jakafi (ruxolitinib) is the established first-line JAK1/2 inhibitor per COMFORT trials — broader experience, also FDA-approved for polycythemia vera and GVHD. Inrebic (fedratinib) is a JAK2/FLT3 inhibitor — alternative first-line or for ruxolitinib failure/intolerance. Newer JAK inhibitors target specific populations: Vonjo for thrombocytopenic MF, Ojjaara for anemic MF.
Why is thiamine monitoring required for Inrebic?
Inrebic carries a boxed warning for fatal encephalopathy including Wernicke’s encephalopathy — caused by thiamine (vitamin B1) deficiency exacerbated by the drug. Mandatory baseline thiamine assessment with supplementation if deficient before initiation. Ongoing monitoring and supplementation. Immediate discontinuation if mental status changes, ataxia, or ocular abnormalities suggest encephalopathy.
Can I take Inrebic if I have low platelet counts?
Caution with thrombocytopenia. Vonjo (pacritinib) is specifically FDA-approved for myelofibrosis with platelets <50,000 — preferred in severe thrombocytopenia. Inrebic and Jakafi may be used with caution and dose adjustment in moderate thrombocytopenia.
Take Control of Your Medication Costs
Targeted JAK2 inhibitor therapy for myelofibrosis should not be derailed by cost. Allogeneic SCT remains the only potentially curative option — consider transplant evaluation early. Our Inrebic advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Inrebic through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.